❓ Is there an ethical difference between withholding and withdrawing life-sustaining treatment?
No. Every major medical ethics body (AMA, AACN, SCCM) holds that there is no ethical or legal distinction between withholding and withdrawing treatment. Both are acceptable when the treatment is no longer consistent with the patient's goals. In practice, withdrawing can feel harder emotionally, but the ethical framework is identical.
❓ What is the principle of double effect and how does it apply here?
The principle of double effect states that an action with both a good effect (relieving suffering) and a foreseeable bad effect (potential respiratory depression) is ethically permissible if: (1) the action itself is not inherently wrong, (2) the intent is the good effect, (3) the bad effect is not the means to the good effect, and (4) there is proportionate reason. Giving morphine for dyspnea during extubation is ethical even if it may hasten death, because the intent is comfort.
❓ What medications should be at the bedside BEFORE palliative extubation?
At minimum: Morphine (for dyspnea/pain), glycopyrrolate (for secretions), lorazepam (for agitation/air hunger), and haloperidol (for terminal delirium). These should be drawn up and ready to administer immediately. Do NOT begin extubation without these available.
Sample Presentation
Mrs. Williams is an 82-year-old woman with metastatic pancreatic cancer, intubated 5 days ago for respiratory failure from bilateral pleural effusions and pneumonia. Despite maximum medical therapy, she has not improved. Family meeting held yesterday with oncology, ICU, and palliative care present. Family reports her advance directive states she would not want prolonged mechanical ventilation. Surrogate (daughter) has elected to transition to comfort-focused care. Plan: discontinue vasopressors, antibiotics, and monitoring. Pre-medicate with morphine 4 mg IV. Extubate at family's readiness. Comfort medications at bedside: morphine drip, glycopyrrolate, lorazepam, haloperidol. Chaplain notified. DNR order in place.
Key Points: Clear goals of care discussion documented. Advance directive supports decision. All comfort medications ready at bedside BEFORE extubation. Monitors will be turned off. Family has been counseled that death may occur in minutes to days. Palliative care team is co-managing. This is ethically and legally supported withdrawal of non-beneficial treatment.
Monitoring
- Comfort assessment, the ONLY vital sign that matters now. Observe for grimacing, accessory muscle use, restlessness, tachypnea as signs of distress.
- Do NOT monitor: SpO2, blood pressure, heart rate on monitors. These are turned off to avoid distressing the family with alarms and numbers.
- Secretion assessment: Listen for "death rattle" (gurgling with respirations). Treat with glycopyrrolate or scopolamine. Reassure family this is not choking or suffering.
- Medication effectiveness: After each dose, reassess in 10-15 minutes. If still distressed, redose or titrate up.
- Bedside nursing, continuous or very frequent (q15-30 min) presence. The patient and family should never be alone during this process.
- Time of death: Pronounce when breathing has ceased and no pulse is palpable. There is no specific observation period required (institutional policies vary, typically 2-5 minutes of apnea).
Comfort Monitoring During Extubation
| Parameter | Focus | Intervention |
| Respiratory distress | Tachypnea, accessory muscle use, nasal flaring, air hunger expression | Opioid bolus (morphine 2โ5 mg IV or hydromorphone 0.2โ0.5 mg IV); titrate infusion upward. Oxygen for comfort only (not SpOโ targets). |
| Secretions / death rattle | Noisy/gurgling breathing from pooled oropharyngeal secretions | Glycopyrrolate 0.2 mg IV/SC q4h PRN, scopolamine patch, or atropine 1% ophthalmic drops 2โ4 sublingual q4h. Reposition. Avoid deep suctioning (traumatic). |
| Agitation / restlessness | Purposeless movement, pulling at lines, facial grimacing | Midazolam 1โ2 mg IV q1h PRN or lorazepam 0.5โ2 mg IV. Escalate to continuous infusion if persistent. Rule out pain, full bladder, positioning. |
| Pain | Grimacing, tachycardia, hypertension (unreliable late), vocalization | Pre-emptive opioid before any repositioning/procedure. Continuous infusion rather than relying on PRN. |
| Family presence | Anyone at bedside; questions; cultural/spiritual needs | Chaplain, social work, bereavement services. Allow family to participate (hand-holding, music). Answer questions honestly. |
| Time of death | Apnea + absent pulse | Pronounce after 2โ5 min of apnea (per institutional policy). Document time. Address family immediately, don't leave. |
Do NOT monitor vital signs as outcome measures. The goal of palliative extubation is comfort, not survival or physiologic targets. Remove SpOโ, BP, and HR displays from the room, they distract family and staff from the human process. Focus on the patient's face, breathing pattern, and family presence.
Transition to Oral Anticoagulation
When stable ร 24-48h (vitals normalized, O2 weaned, troponin trending down): transition from heparin drip to oral DOAC.
- Apixaban: Stop heparin โ start apixaban 10 mg BID ร 7 days โ 5 mg BID. No overlap needed.
- Rivaroxaban: Stop heparin โ start rivaroxaban 15 mg BID ร 21 days โ 20 mg daily. No overlap needed.
- Edoxaban: Requires 5-10 days of parenteral anticoag first โ then edoxaban 60 mg daily.
- Warfarin: Start warfarin while on heparin. Continue heparin until INR 2-3 ร 2 consecutive days (typically 5-7 days overlap).
Follow-Up After Discharge
- 48-72h follow-up after discharge (especially if outpatient PE treatment).
- 3-6 month reassessment: Duration decision (stop vs extend), DOAC adherence, bleeding screening.
- CTEPH screening: If persistent dyspnea at 3-6 months โ echo โ V/Q scan if elevated RVSP.
- Thrombophilia workup: Consider if unprovoked PE in patient < 50 (Factor V Leiden, prothrombin mutation, antiphospholipid antibodies). Test AFTER completing anticoagulation (DOACs and warfarin affect results).
- Cancer screening: If unprovoked PE in patient > 50 โ age-appropriate cancer screening (colonoscopy, mammogram, CT chest, PSA if male).